MEDASORB TECHNOLOGIES CORPORATION is a publicly traded therapeutic device company that has developed a powerful, patented, blood purification technology that can remove unwanted substances from blood and physiologic fluids to treat a number of diseases. CytoSorb TM , the company s flagship product, was designed as a cytokine filter to reduce potentially deadly cytokine storm in critically ill patients with severe sepsis. CytoSorb s blood compatible polymer beads are highly porous, capturing appropriately sized substances in its pores, while letting larger or smaller substances pass around or through. As blood is pumped through a cartridge of these beads using standard dialysis equipment, cytokines and other toxins are captured by the beads and removed from blood. The purified blood is then returned to the patient. CytoSorb TM has shown preliminary clinical benefit in a small human pilot study treated, control in patients with severe sepsis and is currently being used in an up to patient European Sepsis Trial to treat potentially fatal cytokine storm during severe infection and severe sepsis. CytoSorbents, Inc is the operating subsidiary of MedaSorb Technologies Corporation.
Quote | CytoSorbents Corporation (NASDAQ:CTSO)
Last: | $0.95 |
---|---|
Change Percent: | 0.0% |
Open: | $0.91 |
Close: | $0.95 |
High: | $0.96 |
Low: | $0.8624 |
Volume: | 116,409 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | CytoSorbents Corporation (NASDAQ:CTSO)
2024-03-14 22:24:03 ET CytoSorbents Corporation (CTSO) Q4 2023 Earnings Conference Call March 14, 2024 04:30 PM ET Company Participants Eric Ribner - Moderator Phillip P. Chan - Chief Executive Officer Kathleen Bloch - Chief Financial Officer Efthymios N. Del...
2024-03-14 17:09:01 ET More on Cytosorbents Dawson James sees Cytosorbents' Cytosorb as approvable, but raises risk CytoSorbents drops as blood purification system fails key trial Seeking Alpha’s Quant Rating on Cytosorbents Historical earnings data fo...
Message Board Posts | CytoSorbents Corporation (NASDAQ:CTSO)
Subject | By | Source | When |
---|---|---|---|
Plus they have a credit line facility in | Good Sport | investorshub | 07/09/2023 9:53:56 PM |
They won't run out of cash. They have | biotech48 | investorshub | 07/08/2023 9:31:48 PM |
When do they run out of cash? | ranchhand71 | investorshub | 07/07/2023 8:44:14 PM |
PR out that we've completed enrollment. | fantomphan | investorshub | 07/07/2023 12:28:30 PM |
Extracorporeal hemoadsorption therapy as a potential therapeutic option | Good Sport | investorshub | 07/07/2023 2:53:18 AM |
News, Short Squeeze, Breakout and More Instantly...
CytoSorbents Corporation Company Name:
CTSO Stock Symbol:
NASDAQ Market:
CytoSorbents Corporation Website:
STAR-T trial results selected for a Breakout Presentation at the American Association of Thoracic Surgery Annual Meeting in late-April 2024 CytoSorbents intends to submit DrugSorb-ATR for regulatory approval to U.S. Food & Drug Administration (FDA) and Health Canada this year ...
AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...
PRINCETON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening condit...